Oral%20Insulin%20Delivery%20in%20Diabetic%20Rats%20by%20PLGA%20Nanoparticles%20Combined%20with%20a%20Protease%20Inhibitor%20%28N-Ethylmaleimide%29
Abstract

Nanoparticles have shown a certain potential to overcome thedrawbacks of oral peptide delivery in the gastrointestinal tract such as lowpeptide stability and permeability. Insulin PLGA NP were prepared using amodified double emulsion solvent evaporation technique. Insulin PLGA NP were composedfrom human insulin (5 mg) encapsulated in PLGA 2.5% (w/v) mixed with PEG (2kDa, 5% w/w) and the external aqueous phase contained 1.25% of PVA. Theresulting nanoparticles of 202.6 nm diameter and loaded with 33.86 μg insulinper mg of polymer were utilised in this study to examine the hypoglycaemiceffect after combination with a protease inhibitor, N-Ethylmaleimide.

Keywords

Diabetes Mellitus; Nanoparticles; Human Insulin; Protease Inhibitor

How to Cite
Faheem A. M. , Abdeĺkader D. , A. Osman M. , A. McCarron P. & A. El-Gizawy S. (2019) “Oral Insulin Delivery in Diabetic Rats by PLGA Nanoparticles Combined with a Protease Inhibitor (N-Ethylmaleimide)”, British Journal of Pharmacy. 4(1). doi: https://doi.org/10.5920/bjpharm.588

103

Views

38

Downloads

Authors
Ahmed M Faheem (university of sunderland)
Dalia Abdeĺkader (Tanta University)

Mohamed A. Osman (Tanta University)

Paul A. McCarron (Ulster)

Sanaa A. El-Gizawy (Tanta University)
Download
Dates
Licence

Creative Commons Attribution 4.0

Peer Review

This article has been peer reviewed.

File Checksums (MD5)
  • PDF: 84df101dd8d68613d0e37d9490373dcc